Episode 22. Management of Low-Risk MDS

Blood Cancer Talks

Contenido proporcionado por Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

1+ y ago 1:03:46

MP3•Episodio en casa

In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA".
Here are the key studies discussed:

1. ASH choosing wisely:
https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely

2. International Consensus Classification (ICC):
https://pubmed.ncbi.nlm.nih.gov/35767897/

3. WHO classification 2022:
https://pubmed.ncbi.nlm.nih.gov/35732829/

4. IPSS-M:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008

5. Romiplostim in MDS:
https://pubmed.ncbi.nlm.nih.gov/29396092/

6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034

7. Luspatercept in MDS:
https://www.nejm.org/doi/full/10.1056/nejmoa1908892

8. Lenalidomide in MDS:

https://ascopubs.org/doi/10.1200/JCO.2015.66.0118

https://pubmed.ncbi.nlm.nih.gov/21753188/

9.Iron chelation therapy in MDS:

https://pubmed.ncbi.nlm.nih.gov/32203980/

54 episodios

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff

Episode 22. Management of Low-Risk MDS

Blood Cancer Talks

published 1+ y ago